The Circulation Supplement Guide: What The Evidence Shows

The technical word for this category is phlebotonic. It covers oral preparations taken for the symptoms of chronic venous disease: heavy legs, aching, swelling around the ankle by evening, night cramps. They are not treatments for the valves themselves.

The symptoms come from pressure. Leg veins carry blood upwards against gravity using one-way valves and the squeeze of the calf muscle. When valves leak, pressure stays high in the standing leg, fluid is pushed out into the tissue, and the leg feels heavy by the end of the day.

That is the mechanism every plant below is proposed to act on, by one of two routes: tightening vein-wall tone, or reducing capillary leak. MedlinePlus describes the underlying condition in ordinary language, and it is worth reading before any supplement page, including this one.

Start with the ceiling rather than a single plant, because it keeps everything afterwards in proportion. The Cochrane review of phlebotonics for venous insufficiency pooled the randomised evidence across the whole class and found moderate-certainty evidence that they reduce oedema slightly compared with placebo, with low-certainty evidence on most of the symptom outcomes and more side effects than placebo.

Both halves matter. A small real effect on swelling is more than most supplement categories can show, and a long way from what the packaging in this aisle implies.

A newer picture comes from a 2026 network meta-analysis of 51 trials, which ranks the pharmacological options against one another rather than each against placebo. Network analyses are useful for ordering a field and weaker as evidence than a head-to-head trial, and that distinction is worth holding onto.

Against that sits what the specialty recommends. The 2022 vascular surgery guidelines and part II of the same set put compression and procedural treatment at the centre of managing venous disease. Oral preparations appear around the edges of that picture.

If one ingredient on this shelf has earned its place it is horse chestnut seed extract, and the reason is the comparison it survived.

A 1996 Lancet trial compared oral horse chestnut seed extract against compression stockings in people with chronic venous insufficiency, and the extract matched the stockings on lower leg volume over twelve weeks. Compression is the standard of care, so matching it is a serious result rather than a promising one.

The dose was 50 mg of aescin twice daily. Aescin is the standardised marker, so the figure counts the marker rather than the seed, and a label printing neither cannot be compared with it.

The Cochrane review of horse chestnut seed extract pooled seventeen trials and called the extract an efficacious and safe short-term treatment, while asking for more definitive randomised evidence. A meta-analysis of thirteen trials and an earlier criteria-based review reach compatible conclusions, and a placebo-controlled oedema study covers the same ground in deep vein incompetence.

Centella asiatica reaches this category as a titrated triterpenic fraction rather than as the leaf, and its venous trials report doses precisely.

A placebo-controlled trial in venous hypertensive microangiopathy ran the fraction at 60 mg twice daily. A dose-ranging trial compared 30 mg and 60 mg three times a day against placebo for oedema and capillary filtration, and a combined microcirculatory model covers venous hypertension over the same period. A long-haul flight study looked at ankle oedema on medium and long flights, and a further trial ran the same fraction in diabetic microangiopathy.

A systematic review of eight trials gathered that work for chronic venous insufficiency and found signs and symptoms improved, while noting what a reader should note too: the trials are small, several share authors, and much of the literature sits in one journal supplement.

The plant has a separate research life outside veins. A meta-analysis of cognition and mood outcomes, a trial in healthy older volunteers and a 2026 scoping review cover that ground, and a 2021 review of the plant sets out its chemistry. None of that is evidence for a leg, and it is listed here so a reader recognises it when a label borrows it. On safety, an expert panel assessment reviewed Centella-derived ingredients in cosmetic use, a different exposure route from swallowing an extract daily for months.

Ruscus aculeatus reaches the trials almost always inside one fixed combination, and that shapes what its evidence can support.

A meta-analysis of 10,246 subjects pooled the trials of that combination in chronic venous insufficiency, which is by some distance the largest dataset on any plant in this guide. A twelve-week placebo-controlled trial tested a Ruscus preparation against placebo directly, and a European Venous Forum symposium report reviews where the combination sits in current practice.

The composition is the detail worth carrying away: roughly 150 mg of Ruscus extract with 150 mg of hesperidin methyl chalcone and 100 mg of vitamin C per capsule. A bottle naming butcher's broom alone is not carrying what those trials tested, and the two companions are not optional extras.

A case report proposed Ruscus for orthostatic hypotension on the basis of its vasoconstrictor action, a reminder that a plant acting on vessel tone acts on it everywhere rather than only where you want it to.

Two plants here carry cardiovascular research that gets borrowed for legs, and that borrowing is where most of this aisle's overstatement happens.

Hawthorn's serious literature is about heart failure. The Cochrane review assessed extract for chronic heart failure and found benefit on symptoms and exercise tolerance. A dose-comparison trial is the one worth memorising: the standardised extract WS 1442 at 1,800 mg a day for sixteen weeks beat placebo on exercise workload, and the 900 mg arm of the same trial did not. The SPICE trial then ran the same extract in a large heart failure population, and a benefit-risk review weighs the whole of it. A crossover trial of flow-mediated dilation covers a vascular endpoint in prehypertensive adults.

Grape seed sits in blood pressure and endothelial function, not in legs. A dose-response meta-analysis covers flow-mediated dilation, blood pressure and heart rate across controlled trials, a meta-analysis of sixteen trials covers blood pressure specifically, and an earlier meta-analysis covers cardiovascular risk markers. A trial comparing 200 mg and 400 mg a day for twelve weeks found the 400 mg arm dropped systolic pressure by about 13 mmHg in people with prehypertension.

Two interaction facts belong here. A digoxin interaction study examined hawthorn alongside that drug, and a meta-analysis of the hawthorn and camphor combination found that pairing significantly increases blood pressure, which is the opposite of what a buyer would assume from the ingredient. NCCIH's hawthorn page and its grape seed page carry the plain-language versions.

Stone root and motherwort appear on circulation labels regularly. Neither has an oral human trial for venous symptoms at any dose, and saying so is more useful than filling the space with laboratory work about something else.

Stone root's record is two nineteenth-century case notes: an 1887 note in the British Medical Journal and an 1888 note in the South Med Rec. Everything since is chemistry rather than clinical work: a 1999 phytochemistry paper describing a novel flavanone from the plant, and a cell-line screen that included it among many natural products for an entirely different endpoint.

Motherwort has a pharmacological literature and it is not about legs. A review of cardiotonic plants places the genus among plants with traditional cardiac use and few clinical studies; a review of the genus and a review of Herba Leonuri chemistry cover the compounds. The one randomised motherwort trial tested an injection to prevent haemorrhage after induced abortion, which is a different route, a different population and a different purpose.

That is not an accusation that either plant is inert. It is a statement about what has been measured, and a reader deciding where to spend money is entitled to know which names are carried by evidence and which by tradition.

The single most useful habit when reading any supplement page is to ask what amount a cited trial used, then to look for the same amount on the label.

The doses in this guide are not interchangeable. Fifty milligrams of aescin twice daily is a quantity of a standardised marker. Eighteen hundred milligrams a day of WS 1442 is a quantity of one named extract, and the same trial showed half of it did nothing. Sixty milligrams twice daily of a titrated triterpenic fraction is a third kind of number again.

An extract ratio changes everything and is often left off. A 10:1 extract at 100 mg is not 100 mg of dried herb, and a label printing a weight without saying which it means has printed half a fact.

This is why a missing panel is not a cosmetic failing. Without a printed amount none of the research above can be connected to a bottle at all, and the names on the front become a list of things that have been studied rather than a description of what you are swallowing.

Five ingredients, five different kinds of number. Comparing them without reading the third column is how two very different products come to look alike.

A dietary supplement in the United States may make structure and function claims: statements about supporting a normal structure or function of the body. It may not claim to treat, cure or prevent a disease, and a claim that it does turns the product into an unapproved drug.

So supports healthy circulation is inside the line and treats varicose veins is outside it. The FDA's questions and answers on dietary supplements set out the framework, including the point buyers most often miss: these products are not approved before they go on sale.

Two further things are worth knowing. An analysis of supplements implicated in liver injury found the contents frequently mislabelled, which argues for buying through a route with a returns process rather than for avoiding the category. And a systematic review of warfarin interactions catalogues how many botanicals move anticoagulant control, which matters to a great many people reading a circulation page.

• Compression and movement are what the specialty guidelines put first. A supplement sits beside them rather than in place of them.
• Horse chestnut seed extract has the strongest single result in the category, at 50 mg of aescin twice daily.
• Gotu kola and butcher's broom have real venous trials, both at doses a label has to print for the comparison to mean anything.
• Hawthorn and grape seed carry cardiovascular evidence that does not extend to venous symptoms, however often it is implied.
• Stone root and motherwort have no oral human trial in this indication at any dose.
• Eight weeks is the shortest sensible test, so a two-week verdict is a verdict on nothing.

Set that against the product sold on this website and the position is plain. Gluco Mild names five plants with a record and two without, in a liquid taken two drops a day, and publishes no amount for any of them. The ingredients page prints the trial dose beside each name and leaves the bottle's column empty.

That is a documentation failure rather than a claim about what is in the liquid. A formula can be generously made and badly described, and from outside the two are indistinguishable.